Star Combo Pharma (ASX:S66) GF Score: 35/100 (As of Aug. 02, 2026) — 46% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:S66 Star Combo Pharma Ltd ASX:S66
35 GF Score
Price A$0.13
GF Value A$0.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Star Combo Pharma GF Score?

Star Combo Pharma ASX:S66 35 GF Score is 35 as of Aug. 02, 2026, which is 46% above its 10-year median of 24.00. GuruFocus rates ASX:S66 with a GF Score™ of 35/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 2 warning signs investors should review.

Star Combo Pharma has the GF Score of 35, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 4/10
3. Growth Rank : 3/10
4. GF Value Rank : 0/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Star Combo Pharma might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Star Combo Pharma  (ASX:S66) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


Star Combo Pharma GF Score Related Terms


ASX:S66 vs PG, CL, KVUE: GF Score Comparison

For the Household & Personal Products subindustry, Star Combo Pharma's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Star Combo Pharma GF Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's GF Score distribution charts can be found below:

* The bar in red indicates where Star Combo Pharma's GF Score falls into.


ASX:S66
35GF Score
Star Combo Pharma Ltd ASX:S66
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 35 mean?
Star Combo Pharma (ASX:S66) has a GF Score of 35 as of Aug. 02, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Star Combo Pharma and its competitors. This is 46% above median its historical median of 24.00. Over the past decade, Star Combo Pharma's GF Score has ranged from 5.00 to 45.00.
Is Star Combo Pharma's GF Score too high?
Star Combo Pharma's current GF Score of 35 is 46% above median its 10-year median of 24.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 45.00. Overall, Star Combo Pharma has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's GF Score compare to PG and CL?
Star Combo Pharma's GF Score of 35 can be compared against companies in the Consumer Packaged Goods industry. Historically, Star Combo Pharma's own GF Score has ranged from 5.00 to 45.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Consumer Packaged Goods company?
A good GF Score depends on the Consumer Packaged Goods industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Star Combo Pharma and its competitors. Star Combo Pharma's current GF Score is 35, which is 46% above median its own 10-year median of 24.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.13 — trading right at its estimated fair value. The current GF Score is 35, which is 46% above median its 10-year median of 24.00. Star Combo Pharma's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current GF Score is 35 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Star Combo Pharma (ASX:S66) Overvalued in 2026?

Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued. The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13. GuruFocus considers Star Combo Pharma to be Fairly Valued.

Key valuation signals for ASX:S66:

  • GF Score: 35 (46% above median its 10-year median of 24.00)
  • GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
  • GF Score™: 35/100 with 2 warning signs

No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Star Combo Pharma Business Description

Address 171 - 177 Woodpark Road, Smithfield, Sydney, NSW, AUS, 2164
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score

Get the complete analysis for ASX:S66

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price
A$0.13
GF Value